Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

The post Trellis Bioscience secures Series C financing for TRL1068 trial appeared first on Clinical Trials Arena.